Oral contraception: a review.
Syntex Laboratories, Inc., Palo Alto, California.
R A
RA
Edgren
D003276:Contraceptives, Oral / Q000009:adverse effects / Q000266:history* / Q000627:therapeutic use; D005040:Ethynodiol Diacetate / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D049673:History, 20th Century; D006801:Humans; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D009640:Norethindrone / Q000009:adverse effects / Q000627:therapeutic use; D009641:Norethynodrel / Q000009:adverse effects / Q000627:therapeutic use; D009644:Norgestrel / Q000009:adverse effects / Q000627:therapeutic use; D011374:Progesterone / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D003276:Contraceptives, Oral; D009644:Norgestrel; D011374:Progesterone; D005040:Ethynodiol Diacetate; D009641:Norethynodrel; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D009640:Norethindrone